[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.52.4. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 188
Citations 0
Comment & Response
January 2019

Circulating Tumor Cells and Radiotherapy Benefit in Early Breast Cancer

Author Affiliations
  • 1Division of Oncology, Department of Radio-Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
  • 2Radio-Oncology Research Laboratory, Centre Hospitalier Universitaire Vaudois (CHUV), Epalinges, Switzerland
  • 3Department of Radiation Oncology, Hôpital Neuchâtelois, La Chaux-de-Fonds, Switzerland
JAMA Oncol. 2019;5(1):111-112. doi:10.1001/jamaoncol.2018.5077

To the Editor Goodman et al1 recently described a consistent benefit from radiotherapy (RT) in terms of survival and distant disease control after breast-conserving surgery (BCS), but not mastectomy, in 2 cohorts of patients with breast cancer (BC) harboring any circulating tumor cells (CTCs). Speers and Rugo2 emphasize that the lack of benefit from RT in patients with CTC-negative status is probably owing to the study being underpowered to detect small benefits, and the findings should not be regarded as contradictory to abundant randomized evidence of the benefit of RT. We agree and value the identification of a predictive biomarker of RT benefit.

×